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Abstract
Background: Oligoclonal IgG bands in cerebrospinal fluid that are absent in serum indicate intrathecal IgG
synthesis and are a sensitive marker of CNS inflammatory diseases, in particular multiple sclerosis. It may be of
interest to determine whether these bands are predominantly IgG or IgGl.
Methods: We have used Hevylite™ antibodies and developed a technique for detection of oligoclonal IgG and
IgGl bands by means of isoelectric focusing followed by immunoblotting. The same technique was used for
oligoclonal free  and free l detection. Among several techniques tested, affinity immunoblotting appears to be
the most sensitive; it can detect less than 1 ng of IgG or IgGl paraprotein. We compared oligoclonal IgG profiles
with those of oligoclonal IgG and IgGl. There was good agreement concerning the presence or absence of
intrathecal synthesis. We observed the ratios between oligoclonal IgG and IgGl bands, and they did not always
match the ratios between free  and free l bands. We were also able to detect antigen-specific CSF-restricted
oligoclonal IgG and IgGl bands in neuroborreliosis. It remains to be determined subsequently by a clinically-
oriented prospective study, whether predominant IgG/IgGl or free /free l can be observed more frequently in
particular diseases with oligoclonal IgG synthesis.
Discussion: Very sensitive detection of oligoclonal IgG and IgGl bands in cerebrospinal fluid with Hevylite
antibodies is feasible; detection of antigen-specific IgG or IgGl is possible as well. In particular situations, e.g.
when difficulties arise in distinguishing between oligoclonal and monoclonal pattern, the test may be of
considerable clinical value.
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Background
Oligoclonal IgG bands (OCBs) in cerebrospinal fluid
(CSF) that are absent in serum indicate intrathecal IgG
synthesis and are a sensitive marker of CNS inflamma-
tory diseases, in particular multiple sclerosis (MS). Iso-
electric focusing (IEF) and specific IgG detection by
means of immunofixation (IF) or immunoblotting (IB) is
the recommended procedure for OCBs detection [1-3].
It may be of interest to determine whether these bands
are predominantly IgG or IgGl.P r e v i o u sr e p o r t su s e d
either quantitative tests [4-7] or immunofixation with
kappa and lambda antisera [8-10] to demonstrate altered
kappa/lambda or oligoclonal kappa/lambda ratios. How-
ever, these tests were not able to directly distinguish
individual heavy-light chain pairs. Quantitative tests for
total kappa and lambda light chains were neither speci-
fic nor sensitive enough for MS, and their use in CSF
laboratories was almost completely abandoned. In 1989,
Araga et al. described the quantitation of kappa/lambda
ratios of each immunoglobulin (IgG, IgA, and IgM) in
CSF and in sera by means of sandwich enzyme-linked
immunosorbent assay [11]. Since the introduction of
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any medium, provided the original work is properly cited.sheep Hevylite™ antibodies that target epitopes at junc-
tions of the heavy chain and light chain constant
regions, simple single-step analysis of heavy chain-light
chain pairs has been available. The antibodies were
developed for turbidimetric or nephelometric measure-
ments in human sera. Heavy light chain serum immu-
noassays are used in patients with multiple myeloma
and monoclonal gammopathy of undetermined signifi-
cance (MGUS); they can provide quantitative informa-
tion and be of prognostic significance in these patients
[12,13]. In our opinion, these antibodies could be useful
for CSF OCB detection and characterization. Hevylite
antibodies were kindly provided by Dr. L. Assi and Dr.
J. Faint (The Binding Site Ltd., Birmingham, United
Kingdom) and we have developed a technique for the
detection of oligoclonal IgG and IgGl bands. Patterns
o b s e r v e di np a i r e dC S Fa n ds e r u ms a m p l e sw e r ec o m -
pared with patterns of total IgG as well as with the pat-
terns of free light chains (fLC).
Methods
Biotinylation of Hevylite and anti-human free light chain
antibodies
Biotinylation of a portion of Hevylite antibodies and of
antibodies against human free kappa and free lambda
light chains (DAKO, Glostrup, Denmark, Cat. No.
A0100 and A0101, respectively) was performed using
EZ-Link
® NHS-PEO4 Biotinylation Kit (Pierce/Thermo
Scientific, Rockford, USA, Cat. No. 21455). Hevylite
antibodies were diluted to 1.0 g/l in phosphate-buffered
saline (PBS) and proceeded further with buffer exchange
into PBS and biotinylation. As a result, biotinylated anti-
body concentrations fell to 0.8 g/l approximately (due to
the application of the stacker on gel filtration columns).
Based on initial results with dilutions of biotinylated
antibodies 1/200 and 1/1000, dilutions 1/500 for IgG
kappa and 1/800 for IgG lambda were chosen for
further experiments. Biotinylation of fLC antibodies
required no prior buffer exchange since these antibodies
w e r ek n o w nt ob es u p p l i e di nP B S ;t h e s ea n t i b o d i e s
were diluted to 4 g/l in PBS for biotinylation, and bioti-
nylated antibodies were used diluted 1/500 in our assay.
Isoelectric focusing
IEF was performed in 0.5 mm thick agarose gel (1.1%
agarose, 12% sorbitol, and either 6.4% Pharmalyte pH 3-
10 or 6.2% Pharmalyte pH 3-10 plus 1.7% Pharmalyte
pH 8-10.5), without prefocusing, using Multiphor II
apparatus (GE Healthcare, Uppsala, Sweden). Interelec-
trode distance was 8.5 cm. 1700 V, 100 mA, and 10 W
were used as limit values. Samples were applied 2 cm
from the anode into the slots of Servalyt Precotes appli-
cator strips 3.5*2 mm (Serva Electrophoresis GmbH,
Heidelberg, Germany, Cat. No. 42899). IEF was run at
10°C for 1200 Vh (65-70 min).
Affinity-mediated immunoblotting (AIB)
Nitrocellulose (NC) membranes (Amersham™
Hybond™-ECL, GE Healthcare, Cat. No. RPN303D, pore
size 0.45 μm) were coated for 4-8 h with goat anti-
human IgG Fc antibody (AbD Serotec, Oxford, UK, Cat.
No. 5211-8004) diluted to 20 mg/l. Subsequently, the
membranes were rinsed in tris-buffered saline pH 7.6
(TBS) and blocked with 3% bovine serum albumin (BSA,
Serva Electrophoresis GmbH, cat. No. 11924) in TBS for
45-50 min, rinsed in TBS again and laid over the gel, fol-
lowed by 1 sheat of filter paper moistened in TBS and 8
sheets of dry filter paper, a glass plate and a weight
(approximately 0.5 kg). Affinity-mediated blotting was
carried out for 50 min. Membranes were then washed in
TBS and protein fixed with glutardialdehyde (0.25% in
PBS) for 15 min at 4°C. After washing the membranes
three times in TBS, the membrane was re-blocked with
0.3% BSA in TBS for 5-10 min, washed again in TBS, and
biotinylated Hevylite antibody was applied (dilution in
TBS with 0.3% BSA 1/500 for IgG kappa and 1/800 for
IgG lambda) for 75 min. Membranes were washed once
in TBS, twice in TBS-0.05% Tween20 (Serva Electrophor-
esis GmbH, Cat. No. 37470) (TBST), and once in TBS.
Next, alkaline phosphatase streptavidin (Vector Labora-
t o r i e sI n c . ,B u r l i n g a m e ,U S A ,C a t .N o .S A - 5 1 0 0 )d i l u t e d
1/900, was applied for 50 min. After washing once in
TBS, twice in TBST, and twice in TBS, colour reaction
was performed using BCIP/NBT Kit (Vector Laboratories
Inc., Cat. No. SK-5400) until suitable staining developed
(15-25 min). Finally, the membranes were washed in TBS
and deionized water, and dried between two sheets of fil-
ter paper.
For the analysis of total oligoclonal IgG, the procedure
was the same up to the incubation with labeled anti-
body; in this case, we used alkaline phosphatase-conju-
gated anti-human IgG Fc antibody (AbD Serotec,
Oxford, UK, Cat. No. 5211-8104) diluted 1/900 for 75
min and after washing procedure colour reaction was
performed exactly as described above.
For the analysis of Borrelia-specific IgG, IgG,a n d
IgGl, membranes were coated with commercially avail-
able sonicated Borrelia burgdorferi organisms (AbD Ser-
otec, Cat. No. 1440-0006) diluted in TBS to 20 mg/l.
Further steps of the procedure were the same as
described for total oligoclonal IgG, IgG, and IgGl AIB
analysis, except the incubation with biotinylated anti-
body (90 min) and colour development (about 30 min)
was somewhat longer.
Oligoclonal fLC were analyzed by coating the mem-
brane with anti-human kappa or lambda fLC (DAKO,
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mg/l in TBS. The following steps up to the incubation
with the second antibody were exactly as described
above. In-house biotinylated anti-human kappa or
lambda fLC antibodies were used for detection (incuba-
tion time was 90 min for fLC OCBs detection), followed
by the incubation with alkaline phosphatase streptavidin
(see above). Colour development was longer for fLC
than for IgG (about 30 min). For the estimation of assay
sensitivity, commercially available purified human Bence
Jones kappa and lambda free light chains (Bethyl
Laboratories Inc., Montgomery, USA, Cat. No. P80-126
and P80-127, respectively) were used.
Classical immunoblotting
a) Method with biotinylated Hevylite antibody and alkaline
phosphatase streptavidin
Membranes were pre-wetted in deionized water (3-5
min) and then in TBS (30-45 min) and laid over gel, fol-
lowed by 1 sheat of filter paper moistened in TBS and 8
sheets of dry filter paper, a glass plate and a weight.
Blotting was carried out for 30 min. After washing in
TBS, the membranes were blocked with 3% BSA for 60
min and washed 3 times in TBS. Next, biotinylated
Hevylite antibody was applied (dilution 1/500 for IgG
kappa and 1/800 for IgG lambda) for 75 min. Subse-
quent washing and detection were performed exactly as
in the method above.
b) Double antibody method
Membranes were pre-wetted in deionized water (3-5
min) and then in TBS (30-45 minutes) and laid over gel,
followed by 1 sheat of filter paper moistened in TBS
and 8 sheets of dry filter paper, a glass plate and a
weight. Blotting was carried out for 30 min. After the
washing in TBS, the membranes were blocked with 3%
BSA for 60 min, washed 3 times in TBS and Hevylite
antibody was applied (diluted to 1.6 or 8 mg/l for IgG
kappa and 1 or 5 mg/l for IgG lambda) for 75 min.
Membranes were then washed once in TBS, twice in
TBST, and once in TBS. Alkaline phosphatase-conju-
gated AffiniPure rabbit anti-sheep IgG, Fc Fragment
Specific (Jackson ImmunoResearch Europe Ltd., Suffolk,
UK, Cat. No. 313-055-046) was applied for another 75
min. Membranes were then washed once in TBS, twice
in TBST, and twice in TBS. Colour development was
performed as described above.
Routine CSF analyses
For all samples, albumin, IgG, IgM and IgA were mea-
sured in CSF and serum by means of immunonephelo-
metry on Immage analyzer (Beckman Coulter Inc., Brea,
USA). Oligoclonal IgG analysis was performed using a
commercial kit on Hydrasys instrument (Sebia, Évry
Cedex, France, Cat. No. 4355) according to the
manufacturer’s instructions (except that the amount of
t h es a m p l ea p p l i e dw a s1 5μl instead of 10 μl recom-
mended in the instructions). Intrathecal immunoglobu-
lin synthesis was calculated according to Reiber’s
formula [14]. Complete basic CSF diagnostics (cell
count, differential cell count, total protein, lactate, and
glucose) was also performed for all in-house patients.
Samples
To assess the potential use of the method described, we
analyzed 33 samples from 31 patients (MS, n = 5; clini-
cally isolated syndrome, n = 3; neuroborreliosis, n = 5;
AIDS with cerebral toxoplasmosis: n = 1; acute inflam-
matory demyelinating polyneuropathy, n = 2; other diag-
noses, n = 15) for oligoclonal IgG and IgGl; 1 patient
was examined twice and 1 remaining sample was UK
NEQAS quality control sample. Twenty-seven of these
samples were also examined for oligoclonal fLC. Borre-
lia-specific IgG, IgG and IgGl bands were searched for
in 3 samples (1 case each of multiple sclerosis, neuro-
borreliosis, and neuroborreliosis with coincidental
MGUS). For oligoclonal IgG, IgG and IgGl analysis,
samples were diluted to 5 mg/l IgG; for the analysis of
Borrelia-specific OCBs, samples were diluted to 30 mg/l
IgG and 6 μl of diluted sample was applied per lane. For
oligoclonal fLC detection, CSF samples were used undi-
luted, serum samples were diluted 1/100, and 7.5 μl was
applied per lane. All dilutions were performed in 0.8%
saline. Only surplus of CSF and sera after a routine CSF
analysis were used. Diagnoses were searched for in hos-
pital records. The patient mentioned in the Case Report
section gave written informed consent with the publica-
tion of his clinical and laboratory data. Analysis of a lar-
ger number of consecutive paired CSF and serum
samples will follow in a prospective manner to avoid
any possible bias. All samples will be analyzed for IgG,
IgGl,f r e e and free l OCBs and the results will be
compared with clinical data as well as with the data
from the routine CSF analyses.
The study was approved by the local Ethics Commit-
tee (Reference number 615/2011).
Results of preliminary experiments
Affinity-mediated immunoblotting was evaluated as the
most sensitive among the three techniques used. IgG
and IgGl paraproteins were detected in samples con-
taining total IgG at a concentration of 0.2 mg/l, but
even at the concentration of 0.05 mg/l faint bands were
still observed. Biotin-streptavidin amplification step con-
tributed to the sensitivity of the method because the test
for “total” IgG failed to detect 0.05 mg/l concentration
and only faint bands were seen at 0.2 mg/l (Figure 1).
This, however, is of little importance for IgG. Much
more important is to achieve high sensitivity detection
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use polyvinylidene difluoride (PVDF) membranes instead
of nitrocellulose but this added little to the sensitivity of
the method. Additionally, for unknown reasons we
observed a high background on oligoclonal free l light
chain PVDF membranes, which was not observed on
PVDF membranes tested for free , nor on nitrocellu-
lose membranes tested for free  or free l.T h e r e f o r e ,
we decided to use nitrocellulose membranes universally
for all tests. We have tested commercially available puri-
fied human Bence Jones kappa and lambda free light
chains and were able to detect 0.375 ng of free  and
1.5 ng of free l protein.
To assess reproducibility, the same samples were
analyzed four times, twice in gel containing 6.2% Phar-
malyte pH3-10 and 1.7% Pharmalyte pH 8-10.5, and
twice in gel containing 6.4% Pharmalyte pH 3-10 only.
These samples were: Sebia CSF control (Sebia, Cat.
No. 4794) as a positive control (found to contain two
groups of monoclonal-like bands, one each of IgG
and IgGl), intravenous immunoglobulin (Kiovig, Bax-
ter S.A., Lessines, Belgium) as a negative control, one
paired CSF (containing several faint IgG OCBs on IEF/
I F )a n ds e r u m( w i t hn oO C B s )s a m p l e ,a n dt w os e r u m
samples containing paraprotein of the IgG type and
oligoclonal IgG,I g G l,a n df r e e bands, respectively.
OCBs pattern was slightly different depending on the
pH gradient used. Regarding the presence or absence
of bands, however, the results remained the same in
all runs, except for the case of several (three to four)
faint CSF-restricted IgG bands that were barely visi-
ble in two runs when only Pharmalyte pH 3-10 was
used. On the other hand, the bands were clearly visible
in both the runs using Pharmalyte 3-10 plus Pharma-
lyte pH 8-10.5. Several CSF-restricted IgGl bands in
this sample were clearly visible in all four runs. No
cross-reactivity of the serum IgG paraprotein was
seen on the membrane tested for IgGl; several free 
bands in this sample had different migration positions
than IgG bands.
One case of IgGl paraprotein was observed that had
initially been detected on Sebia Hydrasys by IEF fol-
lowed by immunofixation. The sample was from
NEQAS Quality Assurance for oligoclonal IgG and
declared IgG concentrations were 4.0 mg/l in CSF and
1284 mg/l in serum. Interpretation on Sebia Hydrasys
was possible, but more difficult than with AIB. Both
AIB tests detected this paraprotein without any doubt,
while the test for IgGl gave clearer results than the test
for “total” IgG (Figure 2).
No cross-reaction for free light chains was seen using
intravenous immunoglobulin preparation (Flebogamma,
Instituto Grifols, Barcelona, Spain) at a concentration of
250 mg/l.
IgG IgG
S S S S C C C C C C S’ S’ S’ S’ S’ S’ S S S S S S S S
IgG
5 1 0.2 0.05 5 1 0.2 0.05 5 1 0.2 0.05
+
Figure 1 Affinity immunoblots to estimate the detection limit of the IEF/AIB using several IgG paraproteins. From left to right: total IgG,
IgG, IgGl. Based on serum protein electrophoresis and densitometry, serum IgG paraprotein (S) represented 67.6% of total IgG, and serum
IgGl paraprotein (Sl) represented 18.6% of total IgG. Using Hevylite antibodies, S is clearly visible at an IgG concentration 0.05 mg/l, i.e. 0.3 ng
of IgG or 0.2 ng of the paraprotein; Sl is clearly visible at an IgG concentration 0.2 mg/l, i.e. 1.2 ng of IgG or 0.2 ng of the paraprotein (arrows).
In total IgG OCB assay, the detection limit is several times higher but still very good (not higher than 1 ng of paraprotein). The percentage of
paraprotein from total IgG was not known for paired CSF (C) and serum (S’) sample (UK NEQAS Control 8/2011). The anode is at the top. A
mixture of 6.2% Pharmalyte pH 3-10 and 1.7% Pharmalyte pH 8-10.5 was used for isoelectric focusing.
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revealed the presence of CSF-restricted IgG,I g G l,f r e e
,a n df r e el bands in 12/33, 12/33, 16/27, and 11/27
samples, respectively (Table 1). An example of a positive
result in all tests in an MS patient is given in Figure 3.
The presence of OCBs was highly intercorrelated.
Among 13 cases positive for IgG or IgGl OCBs, both
types were seen in 11 cases, the remaining 2 cases hav-
ing IgG or IgGl only. One patient was negative for
IgG OCBs (IEF/IF), but positive when tested with both
Hevylite antibodies (Case No. 14). Numerous identical
bands were seen in CSF and serum; however, Hevylite
antibodies revealed some bands being much stronger in
CSF than in serum. In one additional patient (Case No.
12), no OCBs were revealed by IEF/IF, but 1 band was
observed when tested for total IgG and for IgG by
means of IEF/AIB. Based on recommendations of the
German society for CSF diagnostics and clinical neuro-
chemistry [15], this was considered to be a negative
result. All cases showing CSF-restricted OCBs with
Hevylite antibodies displayed also free  OCBs; these
were, however, observed in 6 cases with negative IgG
OCBs (including 1 borderline result of 1 IgG band
mentioned above). Among 16 samples positive for fLC
OCBs, both fLC OCBs were detected in 11 cases and
only free  OCBs in the remaining 5 cases.
IF, immunofixation (Sebia Hydrasys); AIB, affinity
immunoblotting; MS, multiple sclerosis; CIS, clinically
isolated syndrome; MRI, magnetic resonance imaging;
NB, neuroborreliosis; MGUS, monoclonal gammopathy
of undetermined significance; AIDS, acquired immune
deficiency syndrome; AIDP, acute inflammatory demye-
linating neuropathy; CT, computed tomography; UK
NEQAS, United Kingdom National External Quality
Assurance Scheme
n.d., not determined; +, positive (≥ 2 CSF-restricted
bands); 0, negative; = , no clear preponderance of a par-
ticular IgG-bound or free light chain type
Borrelia-specific IgG, IgG and IgGl bands were
found in one patient with neuroborreliosis, while the
IgG
CS 11 CS 22CS 33CS 44CS 55CS 66
IgG kappa
CS 11 CS 22CS 33CS 44CS 55CS 66
IgG lambda
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Figure 2 Isoelectric focusing/affinity-mediated immunoblotting analysis of IgG (a), IgG (b), IgGl (c), free  (d), - and free l (e) OCBs
in 6 paired CSF (C) and serum (S), C1 -C6,S 1-S 6, cases 9, 33, 29, 30, 31, and 10 (Table 1). CSF 1 and CSF 6 were positive in all tests;
however, the majority of IgG bands were of the lambda type in CSF 1, whereas of the kappa type in CSF 6 (arrowheads). Numerous free  and
free l bands were present in CSF 1, whereas more free  than free l bands were present in CSF 6. Sample 2 is IgGl paraprotein clearly
detected using Hevylite IgGl with no cross-reaction with IgG. Sample 3 represents “type 4”, i.e. bands of equal intensity in CSF and serum that
are both of IgG and IgGl type (arrowheads). No intrathecal synthesis of IgG and no free light chain bands were detected. Finally, samples 4
and 5 represent normal (negative) results with no clear oligoclonal bands. Anode is at the top. A mixture of 6.2% Pharmalyte pH 3-10 and 1.7%
Pharmalyte pH 8-10.5 was used for IgG, IgG, and IgGl, whereas 6.4% Pharmalyte was only used for free  and free l.
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Page 5 of 11Table 1 CSF-restricted oligoclonal IgG, IgG, IgGl, free  and free l bands
No. Diagnosis Cells/
μl
Albumin
quotient
(*10
3)
Intrathecal
Ig fraction
(%)
IgG(IF)
(type)*
IgG
(AIB)
IgG IgGl f fl IgG/
IgGl
f/fl
1 MS 5 2.5 IgG 36%; IgM
30%
+ (type 3) n.d. + + + + = =
2 MS 62 9.6 IgG 65% + (type 2) n.d. + 0 n.
d.
n.
d.
IgG
only
n.d.
3 MS 5 2.9 IgG 30%, IgM
43%
+ (type 2) n.d. + + + + = f >f l
4 MS 5 4.5 IgG 65%
IgM 77%
+ (type 3) + + + + + = =
5 MS 1 3.1 0 + (type 3) n.d. + + n.
d.
n.
d.
= n.d.
6 CIS 6 3.4 0 + (type 2) n.d. 0 + + + IgGl
only
f >f l
7 CIS 3 2.7 0 + (type 3) n.d. + + + + = f >f l
8 CIS 1 3.3 0 + (type 2) + + + + + IgGl >
IgG
=
9 NB 118 37.4 IgM 70% + (type 2) + + + + + IgGl >
IgG
=
10 NB 469 30.0 IgM 40% + (type 2) + + + + + IgG >
IgGl
f >f l
11 NB + MGUS 145 30.0 IgG 30%
IgM 54%
+** (type
3 + type
5)
+** +** + + + IgGl >
IgG
f >f l
12 NB 35 12.8 0 0 (type 1) 0*** 0*** 0 + 0 1 IgG
band
only
f only
13 NB 100 32.8 IgM 42% + (type 3) + + + n.
d.
n.
d.
= n.d.
14 AIDS, cerebral toxoplasmosis 7 10.5 IgM 53% 0 (type 4) n.d. + + + + = f >f l
15 AIDP 3 11.2 0 0 (type 4) 0 0 0 + 0 negative f only
16 AIDP -1st puncture 1 51.5 0 0 (type 4) 0 0 0 + + negative f >f l
17 AIDP - 2nd puncture 1 39.4 0 0(type 4) 0 0 0 + 0 negative f only
18 Oculomotor nerve paresis 3 6.7 0 0 (type 1) n.d. 0 0 n.
d.
n.
d.
negative n.d.
19 Neurodegenerative (parkinsonism) 2 6.2 0 0 (type 1) 0 0 0 + 0 negative 2 weak
f
bands
20 Tension headache 5 6.4 0 0 (type 1) 0 0 0 0 0 negative negative
21 Dorsalgias, myalgias 0 5.3 0 0 (type 1) 0 0 0 0 0 negative negative
22 Memory disturbance 0 3.0 0 0 (type 1) 0 0 0 0 0 negative negative
23 Acute central hemiparesis with complete
regression (post-paroxysmal?; normal brain
MRI)
0 4.0 0 0 (type 4) 0 0 0 0 0 negative negative
24 Posterior columns syndrome, unknown
etiology
3 21.0 IgM 12% 0 (type 1) 0 0 0 + 0 negative f only
25 Lacunar stroke 1 3.9 0 0 (type 1) n.d. 0 0 n.
d.
n.
d.
negative n.d.
26 Gait disturbance, unknown aetiology 0 4.9 0 0 (type 1) n.d. 0 0 n.
d.
n.
d.
negative n.d.
27 Orthostatic hypotension (normal brain MRI) 1 7.5 0 0 (type 1) n.d. 0 0 0 0 negative negative
28 Headache (brain CT negative) 0 3.2 0 0 (type 4) n.d. 0 0 0 0 negative negative
29 Vertigo 1 11.3 0 0 (type 4) 0 0 0 0 0 negative negative
30 Peripheral facial palsy 1 4.0 0 0 (type 1) 0 0 0 0 0 negative negative
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specific bands. No clear-cut bands were seen in one
patient with multiple sclerosis.
Case report
A 69-year-old male was admitted to our hospital with
the diagnosis of acute inflammatory demyelinating poly-
neuropathy (AIDP), based on clinical and EMG findings.
At the neurological exam the patient presented himself
with progressive flaccid quadriparesis and bilateral facial
peripheral palsy. However, CSF analysis revealed lym-
phocytic pleocytosis (145 cells/μl with 85% lymphocytes,
2% plasma cells, 11% monocytes, and 2% neutrophils;
Figure 4a), elevated total protein (1911 mg/l) and lactate
(3.36 mmol/l), severe blood-CSF barrier dysfunction (Q-
Albumin 30.0*10
-3, i.e. 3.5 times the upper age-related
reference limit), and intrathecal synthesis of IgG and
IgM (but not IgA) according to Reiber’sf o r m u l a( I g G ,
30% and IgM, 54%), a pattern highly suggestive of neu-
roborreliosis that was confirmed serologically (IgG anti-
body index 33.5). Routine analysis of IgG OCBs on
Sebia Hydrasys instrument revealed numerous CSF-
restricted OCBs and several faint OCBs identical in CSF
and serum, but also intense paraprotein bands identical
in CSF and serum (Figure 4b). The quantity of parapro-
tein was 6.6 g/l, as determined densitometrically after
serum protein electrophoresis. Additionally, a mild
decrease in polyclonal gamma globulins was observed.
Immunofixation revealed IgG kappa monoclonal band
(Figure 4c).
Unusual combination of neuroborreliosis and mono-
clonal gammopathy made us decide to analyze the
patient’s immunoglobulin profile in CSF and serum in
more detail. Biotinylated Heavylite antibodies were used
for the analysis of IgG and IgGl oligoclonal bands, as
well as Borrelia-specific OCBs. The analysis of total oli-
goclonal IgG and IgGl showed IgG paraprotein both
in CSF and in serum and CSF-restricted oligoclonal
bands were predominantly of the IgGl type. However,
borrelia-specific oligoclonal bands were both of IgG
and IgGl type. (Figure 4d). We confirmed the presence
of IgG paraprotein which did not react with Borrelia
antigen, but probably partly obscured intrathecally
synthesized oligoclonal bands. Both free  and free l
light chain OCBs were detected in CSF but not in
serum; no attempt was made to analyze possible free
light chain OCBs reactivity with Borrelia antigen. Serum
free light chain analysis revealed normal concentrations
and a normal free /free l ratio. Bone marrow aspirate
revealed no malignant cells. After the treatment with
antibiotics and physiotherapy the patient’s clinical status
improved: the patient is self-sufficient and able to walk
with bilateral assistance.
Discussion
Our modification of the IEF/AIB method, based on the
AIB method originally described by Knisley and Rodkey
[16] and adapted for CSF analysis by Kaiser [17] and
Sindic and Laterre [18], uses a glutardialdehyde fixation
step to increase sensitivity [19]. The method was further
modified by using alkaline-phosphatase instead of perox-
idase-based detection. When tested for total oligoclonal
IgG analysis, our method exhibited better analytical sen-
sitivity than the commercial immunofixation method
(Sebia). However, this fact does not seem to add any-
thing to the clinical sensitivity, as no significant
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
Figure 3 Isoelectric focusing/affinity-mediated immunoblotting
analysis of IgG, IgG, IgGl, free , and freel OCBs in a patient
with multiple sclerosis (Case 4 in Table 1) using paired CSF (C)
and serum (S) samples. Several CSF-restricted OCBs that were not
seen in serum samples (arrowheads). Anode is at the top. Samples
were analyzed on the same gel using a mixture of 6.2% Pharmalyte
pH 3-10 and 1.7% Pharmalyte pH 8-10.5.
Table 1 CSF-restricted oligoclonal IgG, IgG?κ?, IgGl?λ?, free ?κ? and free l?λ? bands (Continued)
Lyme arthritis 2 4.2 0 0 (type 4) 0 0 0 0 0 negative negative
32 Polyneuropathy, lumbar disc prolapse 1 7.4 0 0 (type 4) 0 0 0 0 0 negative negative
33 Paraprotein (UK NEQAS sample 8/2011) n.d. n.d. n.d. 0****
(type 5)
0**** 0 0**** 0 0 negative negative
* IEF pattern type according to the international consensus classification [1,15]
** paraprotein IgG detected
*** the presence of only 1 CSF-restricted band was considered to be a negative finding
**** paraprotein IgGl detected
Intrathecal Ig (IgG, IgM, IgA) fraction has been assessed according to Reiber’s formula [14].
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Page 7 of 11difference was observed in the proportion of positive
and negative samples between these two methods [20].
Nevertheless, lowering the detection limit is of crucial
importance for oligoclonal fLC analysis, since these are
present in much lower concentrations in the CSF.
Several authors have reported altered CSF kappa/
lambda ratios [4-7,11,21] as well as predominance of
kappa (using free and bound anti-light chain antisera)
OCBs [8,10,22] in a proportion of patients with MS.
Such conclusions could not be reached in our methodo-
logical study due to a low number of patients tested.
However, we have observed that once oligoclonal IgG
bands are present, they are usually of both IgG as well
as IgGl type and are always accompanied by free  and
often also by free l OCBs. Free  OCBs could rarely be
seen even in the absence of IgG OCBs. The fact that
free l OCBs were less frequently observed could,
however, be explained in part by apparently lower sensi-
tivity of our free l (compared to free ) OCBs test. Dif-
ferences in antibody avidity could also, at least partly,
explain discrepancies among various reports.
Oligoclonal fLC bands of the kappa type are seen in
MS at approximately the same frequency as oligoclonal
IgG; oligoclonal free lambda light chains are less fre-
quently observed [18,23]. Predominantly free  and free
l light chain intrathecal synthesis has been reported in
MS patients and in patients with neuroinfections,
respectively [24]. Although several attempts at fLC
quantitation in CSF have been reported and there is
almost unique agreement that this test may be useful in
the context of the diagnosis of inflammatory CNS dis-
eases, MS in particular [24-31], absolute values mea-
sured are highly discrepant. This is the reason we still
prefer the qualitative IEF method. The observation that
a
c
b
d
C
S
IgG
CS
IgG
CS
IgG
CS
IgG
CS
IgG
CS
IgG
CS
Anti-Borrelia

Figure 4 Case report (case 11 in Table 1): CSF (C)and serum (S) findings. 4a. Lymphocytic pleocytosis and 2 plasma cells in the CSF
cytospin preparation. 4b. Isoelectric focusing/immunofixation using a commercial kit on Hydrasys instrument (Sebia) revealed CSF-restricted
oligoclonal IgG bands as well as identical paraprotein bands in CSF and serum. Anode is on the left. 4c. Serum immunofixation electrophoresis
(Sebia) revealed the presence of IgG monoclonal band (arrow). Anode is at the top. ELP, electrophoresis (general protein stain); G, A, M, K, L:
immunofixation for g, a, μ,  and l chain, respectively. 4 d. Isoelectric focusing/affinity-mediated immunoblotting analysis of case 11: Paraprotein
bands did not react with Borrelia antigen but partly obscured CSF-restricted oligoclonal IgG pattern. Paired CSF and serum samples tested for
(from left to right) “total” IgG, IgG, IgGl; Anti-Borrelia IgG, IgG, IgGl. Anode is at the top. Samples were analyzed on the same gel using a
mixture of 6.2% Pharmalyte pH 3-10 and 1.7% Pharmalyte pH 8-10.5.
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respond to preferential free  or free l synthesis, respec-
tively, is quite surprising.
To our pleasant surprise, Hevylite antibodies can
detect antigen-specific oligoclonal IgG bands. Hence, it
can be concluded that the recognition of epitopes at the
junction of the heavy chain-light chain constant region
is not affected when the IgG molecules to be detected
bind antigen via their antigen-binding site. Except for
the reproducibility experiment mentioned above, we
have always used gels with alkaline extension of the pH
gradient for IgG and IgGl OCBs analysis, whereas free
 and free l OCBs were analyzed deliberately with or
without alkaline extension. Although no differences
were noted, we will prefer to analyze free  and free l
OCBs separately from IgG and IgGl OCBs and with-
out alkaline extension. Alkaline extension is not neces-
sary for free  and free l. From the practical point of
view, it is much more convenient to handle two mem-
branes (tested for IgG and IgGl in one gel, and for
free  and free l in another) than to perform all ana-
lyses simultaneously.
The limits of our study include: 1. no attempt made to
quantitate the relative amount of IgG/IgGl and free
/free l was made; such an attempt was reported for
free  and free l monomers and dimers [32], but it
requires an appropriate software and remains inherently
semi-quantitative at best, although it is probably better
than simple visual inspection; 2. a low number of sam-
ples tested during preliminary experiments which were
concentrated on methodology, with an attempt to show
feasibility of the method to detect IgG and IgGl OCBs
using Hevylite antibodies and to look for a possibility to
compare IgG/IgGl with free /free l profiles. 3. a
need for more extensive reproducibility testing with the
use of more paired CSF and serum samples analyzed at
least twice in different runs.
Nevertheless, the test could be useful at least in some
unusual circumstances, as demonstrated in our case
report. Although monoclonal pattern (type 5) is easily
discerned in typical cases, there are rare cases when dif-
ficulties may arise to distinguish it from type 4 (serum-
derived oligoclonal bands). IgG light chain type and pos-
sibly the presence or absence of reactivity with pre-
sumed responsible microbial agent may provide a clue
in such circumstances. In our case, polyradiculoneuritic
syndrom was clearly attributable to neuroborreliosis,
whereas monoclonal gammopathy of undetermined sig-
nificance (MGUS) was an accidental finding. However,
polyradiculoneuritis associated with multiple myeloma
has been described [33] and could potentially be a dif-
ferential diagnostic problem.
Another possible application of the method is testing
for residual paraproteins in serum and/or urine of
myeloma patients in complete remission (negative
immunofixation electrophoresis), although we do not
dare to extend this hypothesis to other Ig classes since
the interpretation of IEF patterns is difficult for other
monoclonal immunoglobulins than IgG.
Conversely, it would be very interesting to perform
quantitative IgG and IgGl tests with Hevylite antibo-
dies in paired CSF and serum samples if a modification
of this test for CSF becomes available.
Finally, it might be of interest to test for the reactivity
of CSF-restricted oligoclonal fLC bands with microbial
antigens. In our experience, CSF-restricted oligoclonal
fLC are common in neuroborreliosis and there remains
a possibility that oligoclonal fLC (dimers) may have anti-
gen-binding capability [34,35], although this has been
disputed by others [36]. In our case, this opportunity
was missed.
In conclusion, we have adapted an affinity-mediated
immunoblotting technique after IEF for the detection of
IgG and IgGl oligoclonal bands in cerebrospinal fluid
and serum by means of Hevylite antibodies using biotin-
streptavidin amplification step. We compared the results
with those of oligoclonal free light chains tested by a
similar method. The method enables the detection of
IgG and IgGl oligoclonal bands in the same way as for
oligoclonal IgG, without the need of subsequent immu-
nofixation and, presumably, without cross-reactivity with
other immunoglobulins or free light chains. The method
was able to detect less than 1 ng IgG,I g G l or free 
light chain monoclonal protein and approximately 1.5
ng of free l light chain monoclonal protein correspond-
ing to the concentration of 0.2 mg/l for free l light
chains and even less for IgG,I g G l and free  light
chains.
The proportion between IgG and IgGl bands in
individual patients is variable and does not always corre-
spond with the proportion between free  and free l
bands. It remains to be determined whether this test
adds anything clinically useful to the routine oligoclonal
IgG bands detection or whether predominant IgG/
IgGl or free /free l pattern can be observed more fre-
quently in certain diseases with oligoclonal IgG synth-
esis. The comparison (albeit only qualitative) of the
intensity of oligoclonal IgG versus IgGl as well as free
 versus free l may be of theoretical interest. At least in
some circumstances our method seems to be useful
clinically, e.g. in rare cases where difficulties arise in the
differentiation between type 4 (systemic oligoclonal pat-
tern) and type 5 (monoclonal pattern).
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